# Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

> **NCT03524326** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Cutaneous Squamous Cell Carcinoma
- Head and Neck Cancer
- Head and Neck Carcinoma

## Interventions

- **DRUG:** Lenvatinib Pill
- **DRUG:** Lenvatinib Pill
- **DRUG:** Lenvatinib Pill
- **DRUG:** Cetuximab
- **DRUG:** Lenvatinib Pill
- **DRUG:** Lenvatinib Pill

## Key facts

- **NCT ID:** NCT03524326
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-30
- **Primary completion:** 2022-10-13
- **Final completion:** 2022-10-13
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03524326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03524326, "Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03524326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*